2-氨基-5-溴-4-氟苯甲酸 | 143945-65-7

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-溴-4-氟苯甲酸
• 英文名称: 2-amino-5-bromo-4-fluorobenzoic acid
• 英文别名: 2-amino-4-fluoro-5-bromobenzoic acid
• CAS: 143945-65-7
• 化学式: C₇H₅BrFNO₂
• mdl: MFCD06409112
• 分子量: 234.025
• InChiKey: RPHQHEBXMAGQKB-UHFFFAOYSA-N

物化性质

• 熔点：
  215-217°C
• 沸点：
  343.6±42.0 °C(Predicted)
• 密度：
  1.877±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在2-8°C的环境中，并避免光照，同时需保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-5-bromo-4-fluorobenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-5-bromo-4-fluorobenzoic acid
CAS number: 143945-65-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrFNO2
Molecular weight: 234

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-氨基-5-溴-4-氟苯甲酸是一种有机中间体，文献报道溴代试剂可以选用NBS或溴。

该化合物可通过将2-氨基-4-氟苯甲酸进行溴代反应而制备。

反应信息

• 作为反应物：
  描述：

  2-氨基-5-溴-4-氟苯甲酸 在 盐酸 、 三乙基硅烷 、 正丁基锂 、 草酰氯 、 三氟甲磺酸 、 sodium hydride 、 三乙胺 、 N,N-二甲基甲酰胺 、 三氟乙酸 、 copper(l) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 10.0h， 生成 (2S,3R,4S,5S,6R)-2-(4-chloro-5-(4-ethylbenzyl)-2-(methoxy-d3)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
  参考文献：
  名称：

  [EN] DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE
  [FR] DÉRIVÉS DE BENZYLBENZÈNE DEUTÉRÉS ET PROCÉDÉS D'UTILISATION

  摘要：

  提供了对钠依赖性葡萄糖共转运蛋白SGLT具有抑制作用的化合物。本发明还提供了制药组合物、制备这些化合物的方法、合成中间体以及使用这些化合物的方法，可以独立使用或与其他治疗剂联合使用，用于治疗受SGLT抑制影响的疾病和病况。

  公开号：

  WO2010009243A1
• 作为产物：
  描述：

  2-氨基-4-氟苯甲酸 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以76%的产率得到2-氨基-5-溴-4-氟苯甲酸
  参考文献：
  名称：

  MAP855 的发现，一种具有 ATP 竞争作用模式的有效和选择性 MEK1/2 抑制剂

  摘要：

  MEK1/2 的突变被描述为对 BRAF/MEK 抑制剂治疗的抗性机制。我们报告了一种在野生型 (WT) 和突变型 MEK12 模型中具有功效的新型 ATP 竞争性 MEK1/2 抑制剂的发现。从 HTS 命中开始，我们获得了对 WT MEK1/2 和一组 MEK1/2 突变细胞系具有等效抑制作用的选择性细胞活性化合物。使用基于结构的方法，优化通过对分子匹配对 (MMP) 和配体构象的系统分析来解决问题。向早期工具化合物6中仅添加三个重原子消除了 Cyp3A4 的责任，并将细胞效力提高了 100 倍，同时将 log P降低了 5 个单位。MAP855 的分析，化合物30，在 BRAF 突变模型的药代动力学-药效学和功效研究中显示出与临床 MEK1/2 抑制剂相当的功效。化合物30是一种新型的高效选择性 MEK1/2 激酶抑制剂，对 WT 和突变型 MEK1/2 具有等效抑制作用，其药物样特性允许进一步研究

  DOI：

  10.1021/acs.jmedchem.1c02192

文献信息

• Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators
  作者：Anthony B. Pinkerton、Satyamaheshwar Peddibhotla、Fusayo Yamamoto、Lauren M. Slosky、Yushi Bai、Patrick Maloney、Paul Hershberger、Michael P. Hedrick、Bekhi Falter、Robert J. Ardecky、Layton H. Smith、Thomas D. Y. Chung、Michael R. Jackson、Marc G. Caron、Lawrence S. Barak

  DOI：10.1021/acs.jmedchem.9b00340

  日期：2019.9.12

  Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based

  神经降压素受体1（NTR1）是一种G蛋白偶联受体，在整个中枢神经系统中广泛表达，在其中它充当神经调节剂。神经降压素受体与多种中枢神经系统疾病有关，但是尽管为开发小分子配体付出了巨大的努力，但很少有此类化合物的报道。在这里，我们描述了基于喹唑啉的铅的优化，以得到18（SBI-553），这是一种有效的脑渗透NTR1变构调节剂。
• STING AGONISTIC COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20210253615A1

  公开（公告）日：2021-08-19

  A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

  一种包含具有对STING具有激动活性的化合物的药物或制剂作为活性成分，其中该化合物由以下一般式（I-1）表示： 其中所有符号表示规范中描述的相同含义，该化合物可用作抑制癌症或传染病的进展、抑制复发和/或治疗的制剂的活性成分。
• [EN] NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS<br/>[FR] NOUVELLES QUINAZOLINES À SUBSTITUTION BENZYLAMINO ET LEURS DÉRIVÉS EN TANT QU'INHIBITEURS DE SOS1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018115380A1

  公开（公告）日：2018-06-28

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式（I）的化合物，其中基团R1至R7具有权利要求和说明中给定的含义，它们作为SOS1的抑制剂的用途，包含这种化合物的药物组合物以及它们作为药物/医疗用途的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• Quinazolinone Compound and Application Thereof
  申请人：LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.

  公开号：US20200317660A1

  公开（公告）日：2020-10-08

  The present invention relates to a series of quinazolinone compounds and applications thereof as PI3Kα inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.

  本发明涉及一系列喹唑啉酮化合物及其作为PI3Kα抑制剂的应用。具体而言，本发明涉及一种在式（I）中显示的化合物及其互变异构体或药用可接受的盐。
• [EN] FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS DE QUINOLÉINE ET DE QUINOXALINE FLUORÉS UTILISÉS EN TANT QU'INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE (DHODH) POUR LE TRAITEMENT DU CANCER, DE MALADIES AUTO-IMMUNES ET INFLAMMATOIRES
  申请人：JANSSEN BIOTECH INC

  公开号：WO2021084500A1

  公开（公告）日：2021-05-06

  The present invention discloses compounds formula (I): (I) wherein X is CH; The present compounds of formula (I) are dihydroorotate dehydrogenase (DHODH) inhibitors, and are useful for the treatment of inflammatory disorders, autoimmune disorders and cancer, such as e.g. lymphomas, leukemias, carcinomas, and sarcomas. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 60 to 136; examples 1 to 39; tables 1 and 2). An exemplary compound is e.g. : 4-ethyl-1-(7-fluoro-4-isopropyl-2- (2-methoxyphenyl)quinolin-6-yl)-3-(hydroxymethyl)-1H-1,2,4- triazol-5(4H)-one (example 1): (AA)

  本发明公开了化合物式(I)：(I)其中X为CH；本发明的式(I)化合物是二氢乳酸脱氢酶(DHODH)抑制剂，适用于治疗炎症性疾病、自身免疫性疾病和癌症，例如淋巴瘤、白血病、癌瘤和肉瘤等。本说明公开了示例化合物的合成和表征，以及其药理数据（例如第60至136页；示例1至39；表1和表2）。示例化合物例如为：4-乙基-1-(7-氟-4-异丙基-2-(2-甲氧基苯基)喹啉-6-基)-3-(羟甲基)-1H-1,2,4-三唑-5(4H)-酮（示例1）：(AA)